Contents:

1 Executive Summary 2 Methodology 3 Table of Contents 3 1 List of Boxes 3 2 List of Figures 3 3 List of Tables 4 Lymphoma Therapeutics 4 1 Introduction 4 1 1 Disease Definition 4 1 2 Etiology & Pathophysiology 4 1 3 Epidemiology 4 2 Current Treatment Strategies 4 2 1 Hodgkin's Disease 4 2 2 Non-Hodgkin's Lymphoma 4 2 3 Prognosis 4 3 Progress in Current Treatment Strategies 4 3 1 HODGKIN 4 3 2 NON-HODGKIN 4 4 Key Therapeutic Strategies 4 4 1 Antibodies & Immunostimulation 4 4 2 Small molecules: Apoptosis inducers & Kinase inhibitors 4 5 Current Drug Development: The Late Stage Pipeline 4 5 1 Progress Analysis: aldesleukin 4 5 2 Progress Analysis: Arsenic trioxide 4 5 3 Progress Analysis: BiovaxID 4 5 4 Progress Analysis: bortezomib 4 5 5 Progress Analysis: LymphoCide 4 5 6 Progress Analysis: FavId 4 5 7 Progress Analysis: MyVax 4 5 8 Progress Analysis: Nelarabine 4 5 9 Progress Analysis: Genasense 4 5 10 Progress Analysis: Marqibo 4 5 11 Progress Analysis: Pixantrone 4 5 12 Progress Analysis: CCI-779 4 5 13 Progress Analysis: HuMax-CD4 4 5 14 Progress Analysis: Bortezomib 4 6 Current Drug Development: The Early Stage Pipeline 4 6 1 Progress analysis: bevacizumab 4 6 2 Progress Analysis: CMC-544 4 6 3 Progress Analysis: galiximab 4 6 4 Progress Analysis: LY317615 4 6 5 Progress Analysis: SGN-40 4 6 6 Progress Analysis: Hu1D10 4 6 7 Progress Analysis: SGN-30 5 Therapeutic Antibodies 5 1 Key Developmental Strategies 5 2 Treating Colorectal Cancer 5 2 1 Avastin 5 2 2 Erbitux 5 3 Treating Lymphomas 5 3 1 Rituxan 5 3 2 Bexxar 5 3 3 Zevalin 5 4 Treating Leukemias 5 4 1 ALL 5 4 2 CLL 5 4 3 AML 5 4 4 CML 5 4 5 Campath 5 4 6 Mylotarg 5 5 Treating Lung cancer 5 5 1 Cotara 5 6 Antibody Deals on the Rise 5 6 1 Antibody Deals in Phase III 5 6 2 Antibody Deals in Phase II 5 7 New Approaches in Antibody Delivery and Design – The Next Generation 5 7 1 How to Make Them Smaller and Different? 5 7 2 Biomaterials in Sustained Delivery Applications 5 7 3 Gene delivery – the Future? 5 8 Current Analysis of Antibodies in Clinical Development 5 8 1 Prostate Cancer Therapeutics 5 8 2 Breast Cancer Therapeutics 5 8 3 Colorectal Cancer Therapeutics 5 8 4 Melanoma Therapeutics 5 8 5 Hematological Cancers Therapeutics 5 9 Antibodies in Phase III Clinical Development 5 9 1 Progress Analysis: IGN 101 5 9 2 Progress Analysis: MDX 010 5 9 3 Progress Analysis: ONYVAX 105 5 9 4 Progress Analysis: Ovarex 5 9 5 Progress Analysis: Panitumumab 5 9 6 Progress Analysis: RENCAREX 5 9 7 Progress Analysis: Nimotuzumab 5 9 8 Progress Analysis: TransMID 5 9 9 Progress Analysis: Lintuzumab 5 9 10 Progress Analysis: Zanolimumab 5 10 Antibodies in Phase II Clinical Development 5 10 1 Progress Analysis: ABT-510 5 10 2 Progress Analysis: BB 10901 5 10 3 Progress Analysis: CP 675206 5 10 4 Progress Analysis: CNTO-328 5 10 5 Progress Analysis: Ecromeximab 5 10 6 Progress Analysis: EMD 273063 5 10 7 Progress Analysis: WX-G250RIT 5 10 8 Progress Analysis: HGS-ETR1 5 10 9 Progress Analysis: HuMax-CD20 5 10 10 Progress Analysis: HuMax-EGFr 5 10 11 Progress Analysis: Galiximab 5 10 12 Progress Analysis: PROXINIUM 5 10 13 Progress Analysis: RAV12 5 10 14 Progress Analysis: SGN-15 5 10 15 Progress Analysis: SGN-30 5 10 16 Progression Analysis: VEGF-Trap 5 10 17 Progress Analysis: MEDI 522 5 10 18 Progress Analysis: Volociximab 5 11 Cancer Therapeutic Antibodies in Clinical Development 6 Protein Kinase Inhibitors 6 1 Rationale for Development of Kinase Inhibitors in Oncology 6 2 Protein Kinase Targets – A Growing Family 6 3 Challenges in Protein Kinase Drug Discovery 6 3 1 Enabling Structure-Based Drug Design is the Key 6 3 2 Specific Kinase Inhibitors without Kinase Profiling? 6 4 Drugs according to Target 6 4 1 Cyclin-dependent Kinase Target Inhibitors 6 4 2 Aurora Kinase Target Inhibitors 6 4 3 Cell Cycle Checkpoint Target Controls Inhibitors 6 4 4 Tyrosine Kinase Receptor Inhibitors 6 4 5 Other Serine/Threonine Kinase Target Inhibitors 6 5 Dual or Multiple Kinase Inhibitor Analysis 6 5 1 Presentation of Drugs Targeting A to F Kinases 6 5 2 Presentation of Drugs Targeting G to T Kinases 6 6 Targets According to Indication 6 6 1 Breast Cancer 6 6 2 Prostate Cancer: What Cannot be Found in the ‘Groins’? 6 6 3 Lung Cancer: A Need for Improved Survival Rates 6 6 4 Colorectal Cancer: EGFR & VEGFR are Strong Targets but There are Others 6 6 5 Leukemia: Show Me the Power of PKI 6 6 6 Melanoma 6 6 7 Lymphoma: We Are In 6 7 Growing Competition in the Field 6 8 Big Pharma Outlook: The Race is On 6 8 1 Novartis Deals - Digs Deeper into Cell Cycle Inhibitors 6 8 2 AstraZeneca – Wheeling and Dealing 6 8 3 Pfizer’s Long Look at OSI Pharmaceuticals 6 8 4 GlaxoSmithKline Gains Momentum 6 9 Strategic Deals Creating Competitive Edge 6 9 1 Mergers 6 9 2 Astex – the PKI Switchboard 6 9 3 Big Pharma’s Darling 6 10 Current Protein Kinase Inhibitors in Therapy 6 10 1 Mechanism, Target and Developmental History 6 10 2 Approvals: Indications & Markets 6 11 Protein Kinase Inhibitors in Drug Development – A Progress Analysis 6 11 1 Progress Analysis - Breast Cancer 6 11 2 Progress Analysis - Prostate Cancer 6 11 3 Progress Analysis - Lung Cancer 6 11 4 Progress Analysis - Colorectal Cancer 6 11 5 Progress Analysis - Leukemia 6 11 6 Progress Analysis – Melanoma 6 11 7 Progress Analysis - Lymphoma 7 Appendix I: Selected Company R&D Summarizes in Lymphoma 7 1 1 Accentia BioPharmaceuticals 7 1 2 Biogen Idec 7 1 3 Cell Therapeutics 7 1 4 Chiron Corporation 7 1 5 Cephalon 7 1 6 Eli Lilly 7 1 7 Favrille 7 1 8 Genentech 7 1 9 Genitope Corporation 7 1 10 Genmab 7 1 11 Genta 7 1 12 GlaxoSmithKline 7 1 13 Immunomedics 7 1 14 Inex Pharmaceuticals 7 1 15 Millennium Pharmaceuticals 7 1 16 Protein Design Labs 7 1 17 Roche 7 1 18 Sanofi-Aventis 7 1 19 Seattle Genetics 7 1 20 Wyeth Company index Drug index List of Boxes Box 1 Possible Complications of Treatment Box 2 Updated REAL/WHO Classification for B-Cell Neoplasms Box 3 Subclassification of stage Box 4 Updated REAL/WHO Classification for B-Cell Neoplasms Box 5 Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms Box 6 Staging subclassification system Box 7 Study details Box 8: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology Box 9: Marrion’s Drug Delivery Technology Box 10: Quick Facts – IGN 101 Box 11: Quick Facts – MDX 010 Box 12: Quick Facts – ONYVAX 105 Box 13: Quick Facts - Ovarex Box 14: Quick Facts – Panitumumab Box 15: Quick Facts - RENCARNEX Box 16: Quick Facts - Nimotuzumab Box 17: Quick Facts - RENCARNEX Box 18: Quick Facts - Lintuzumab Box 19: Quick Facts - Zanolimumab Box 20: Quick Facts – ABT-510 Box 21: Quick Facts – BB 10901 Box 22: Quick Facts – CP-675206 Box 23: Quick Facts – CNTO-328 Box 24: Quick Facts - Ecromeximab Box 25: Quick Facts – EMD-273063 Box 26: Quick Facts – WX-G250RIT Box 27: Quick Facts – HGS-ETR1 Box 28: Quick Facts – HuMax-CD20 Box 29: Quick Facts – HuMax-EGFr Box 30: Quick Facts – Galiximab Box 31: Quick Facts – PROXINIUM Box 32: Quick Facts – RAV12 Box 33: Quick Facts –SGN-15 Box 34: Quick Facts –SGN-30 Box 35: Quick Facts – VEGF-Trap Box 36: Quick Facts – MEDI 522 Box 37: Quick Facts – Volociximab Box 38: The Power of Ambit’s Kinase Profiling Box 39: Summary Terms of the Exelixis Transaction List of Figures Figure 1 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways Figure 2 Top 10 PKI Drug Developing Companies Figure 3 Clinical Trial Distribution in Breast Cancer for PKI Drugs Figure 4 Clinical Trial Distribution in Prostate Cancer for PKI Drugs Figure 5 Clinical Trial Distribution in Lung Cancer for PKI Drugs Figure 6 Clinical Trial Distribution in Colorectal Cancer for PKI Drugs Figure 7 Clinical Trial Distribution in Leukemia for PKI Drugs Figure 8 Clinical Trial Distribution in Melanoma for PKI Drugs Figure 9 Clinical Trial Distribution in Lymphoma for PKI Drugs List of Tables Table 1 Drugs used in the treatment of lymphoma Table 2 Summary of Strategies Enhancing Antibody Function Table 3 Cancer immunotherapy strategies Table 4 Protein Kinase Targets in Clinical Trials for Lymphoma Table 5 Recent published studies Aldesleukin Table 6 Recent published studies Arsenic trioxide Table 7 Recent published studies BiovaxID Table 8 Recent Published Studies Bortezomib Table 9 Recent published studies epratuzumab Table 10 Recent published studies FavId Table 11 Recent published studies MyVax Table 12 Recent published studies Nelarabine Table 13 Recent published studies Genasense Table 14 Recent published studies Pixantrone Table 15 Recent published studies temsirolimus Table 16 Recent published studies Zanolimumab Table 17 Recent published studies Flavopiridol Table 18 Recent published studies bevacizumab Table 19 Recent published studies CMC-544 Table 20 Recent published studies galiximab Table 21 Recent published studies LY317615 Table 22 Recent published studies SGN-40 Table 23 Recent published studies Apolizumab Table 24 Recent published studies SGN-30 Table 25: Summary of Strategies Enhancing Antibody Function Table 26: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies Table 27: Drug Delivery Companies with Cancer Focus Table 28: FDA Approved Polymer-based Drug Delivery Systems for Cancer Table 29: Antibody Therapeutics in Prostate Cancer Table 30: Antibody Therapeutics in Breast Cancer Table 31: Antibody Therapeutics in Colorectal Cancer Table 32: Antibody Therapeutics in Melanoma Table 33: Antibody Therapeutics in Hematological Cancer Table 34: MDX-010’s Collaborative History and Landscape Table 35: Overview of Targets in Commercial Development Table 36: Cyclin-dependent Kinase Targets in Development Table 37: Aurora Kinase Targets in Development Table 38: Cell Cycle Checkpoint Targets in Development Table 39: Epidermal Growth Factor Receptor Targets in Development Table 40: FMS-like tyrosine kinases and their Synonyms Table 41: Fms-related Tyrosine Kinase Targets in Development Table 42: Platelet-derived Growth Factor Receptor Targets in Development Table 43: Kinase Insert Domain Targets in Development Table 44: Drugs in Development Targeting the PI3K/Akt/mTOR pathway Table 45: Drugs in Development Targeting the Ras-Raf-MEK-ERK (ERK) pathway Table 46: Serine/Threonine Kinase Inhibitors in Development Table 47: Protein Kinase Targets in Clinical Trials for Breast Cancer Table 48: Protein Kinase Targets in Clinical Trials for Prostate Cancer Table 49: Protein Kinase Targets in Clinical Trials for Lung Cancer Table 50: Protein Kinase Targets in Clinical Trials for Colorectal Cancer Table 51: Protein Kinase Targets in Clinical Trials for Leukemia Table 52: Protein Kinase Targets in Clinical Trials for Melanoma Table 53: Protein Kinase Targets in Clinical Trials for Lymphoma Table 54: Drugs in Therapy – Mechanism & Targets Table 55: Current and Developmental History of PKI Drugs in Therapy Table 56: Approvals: Indications & Markets Table 57: Top 10 Drugs in Terms of Number of Clinical Trials Table 58: List of Cancer Indications Targeted by Protein Kinase Inhibitors Table 59: PKI Drugs in Development for Breast Cancer Table 60: PKI Drugs in Development for Prostate Cancer Table 61: PKI Drugs in Development for Lung Cancer Table 62: PKI Drugs in Development for Colorectal Cancer Table 63: PKI Drugs in Development for Leukemia Table 64: PKI Drugs in Development for Melanoma Table 65: PKI Drugs in Development for Lymphoma Table 66 Accentia BioPharmaceuticals anticancer pipeline Table 67 Biogen anticancer pipeline Table 68 Cell Therapeutics anticancer pipeline Table 69 Chiron Corporation anticancer pipeline Table 70 Cephalon anticancer pipeline Table 71 Eli Lilly anticancer pipeline Table 72 Favrille anticancer pipeline Table 73 Genentech anticancer pipeline Table 74Genitope anticancer pipeline Table 75 Genmab anticancer pipeline Table 76 Genta anticancer pipeline Table 77 GlaxoSmithKline anticancer pipeline Table 78 Immunomedics anticancer pipeline Table 79 Inex Pharmaceuticals anticancer pipeline Table 80 Millennium Pharmaceuticals anticancer pipeline Table 81 Protein Design Labs anticancer pipeline Table 82 Roche anticancer pipeline Table 83 Sanofi-Aventis anticancer pipeline Table 84 Seattle Genetics anticancer pipeline Table 85 Wyeth anticancer pipeline

Companies Mentioned

- Accentia BioPharmaceuticals - Biogen Idec - Cell Therapeutics - Chiron Corporation - Cephalon - Eli Lilly - Favrille - Genentech - Genitope Corporation - Genmab - Genta - GlaxoSmithKline - Immunomedics - Inex Pharmaceuticals - Millennium Pharmaceuticals - Protein Design Labs - Roche - Sanofi-Aventis - Seattle Genetics - Wyeth